The Week in Review: Transactions and Approvals

Qiming Venture Partners announced a 250 million RMB ($36.7 million) fund to develop Beijing biomedical companies; Jana Partners will try to stop Charles River Labs’ acquisition of WuXi PharmaTech; Anhui Anke Biotech paid 7 million RMB ($1 million) for a 70% stake in Zhejiang Fuwei Pharma; Simcere (先声药业) will increase its ownership of Boda Pharma to 90%; Beike Biotech formed a JV with SiriCell Technologies of Bangkok; TauRx Pharma and Bayer will collaborate to develop diagnostic tools for Alzheimer’s; China Medical Technologies (中国医疗技术公司) received SFDA approval for its HPV test; Roche’s Tarveca increased survival among patients with a form of non-small cell lung cancer (NSLC) common in Asian patients; and Beike Biotech reported early success for umbilical cord mesenchymal stem cell transplants. More details… Stock Symbols: (NYSE: CRL) (NYSE: WX) (SZEX: 300009) (NYSE: SCR) (XETRA: BAY) (NSDQ: CMED) (SVX: ROG)